Pfizer’s decision to offload $3.05 billion worth of shares in Haleon is a strategic move driven by shifting priorities in a volatile pharmaceutical market. The transaction, involving 700 million ...

Pfizer PFE-2.36%decrease; red down pointing triangle has sold 700 million shares in British consumer-healthcare business Haleon HLN 1.12%increase; green up pointing triangle for 2.50 billion ...

Based in the United Kingdom, Haleon makes consumer health care products, including Advil, Centrum Multivitamin and Aquafresh ...

Once complete, Pfizer's stake in Haleon will fall from 15.0% to around 7.3%. Pfizer's move comes after Haleon's spin-off as an independent consumer healthcare company, part of plans to reshape its ...

Pfizer (PFE) announces that it intends to sell approximately 700M ordinary shares in Haleon plc (HLN), representing approximately 7.7% of Haleon’s issued share capital. “There will be no sale ...

Wednesday announced the sale of 700 million shares in Haleon Plc (HLN), a British multinational consumer healthcare ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

The UK-based consumer healthcare company will be modernizing its facility along Brook Road, where it conducts R&D for such ...

Highlights,Pfizer Inc. plans to reduce its stake in Haleon PLC by selling approximately 700 million shares, representing 7.7% of the company.,The sale will take place via an accelerated book-building ...

The sale of 700 million Haleon shares at 357 pence apiece is a discount of about 2.8% to the stock's closing price on Tuesday. The sale represents nearly 7.7% of the issued share capital of Haleon, ...

Pfizer has sold 700 million shares in British consumer-healthcare business Haleon for 2.50 billion pounds, equivalent to US$3.05 billion, it said in a statement. The U.S. drugmaker said Wednesday ...

Once complete, Pfizer's stake in Haleon will fall from 15.0% to around 7.3%. Pfizer's move comes after Haleon's spin-off as an independent consumer healthcare company, part of plans to reshape its ...